ESPR received a significant boost as bempedoic acid was the only non-statin newly recommended in the 2025 ESC/EAS guidelines for lowering LDL-C and reducing cardiovascular risk, achieving Class I or IIa recommendations across multiple patient groups. This endorsement reinforces Esperion’s European growth via Daiichi Sankyo and supports its U.S. strategy, including plans to advance oral triple combination therapies targeting earlier and more aggressive LDL-C management
$Esperion(ESPR)$